Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 February 2008, Vol. 111, No. 4, pp. 2152-2154.
Prepublished online as a Blood First Edition Paper on November 28, 2007; DOI 10.1182/blood-2007-10-116111.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-10-116111v1
111/4/2152    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lob, S.
Right arrow Articles by Terness, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lob, S.
Right arrow Articles by Terness, P.
Related Collections
Right arrow Immunobiology
Right arrow Brief Reports
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

IMMUNOBIOLOGY

Brief Report

Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells

Stefan Lob1,2, Alfred Konigsrainer1, Richard Schafer3, Hans-Georg Rammensee2, Gerhard Opelz4, and Peter Terness4

1 Department of General, Visceral and Transplant Surgery, University Hospital of Tubingen, Tubingen; 2 Institute for Cell Biology, Department of Immunology, Eberhard Karls University of Tubingen, Tubingen; 3 Institute of Clinical and Experimental Transfusion Medicine, Eberhard Karls University of Tubingen, Tubingen; and 4 Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany

Clinical trials have been started with the aim of inducing tumor immunity by blocking the immunosuppressive action of indoleamine-2,3-dioxygenase (IDO) with the IDO2-inhibitor dextro-1-methyl-tryptophan (D-1MT). Here we show that human dendritic cells (DCs) express both IDO-1 and IDO-2, but that only IDO1 mediates tryptophan catabolism; furthermore, its activity is blocked by levo-1MT, whereas D-1MT is inefficient. Consequently, in humans any possible antitumor effects of D-1MT cannot be attributed to abrogation of IDO activity in DCs as described in this study.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020